Braidwell »

Dianthus Therapeutics shares owned by Braidwell

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Braidwell

Quarter filed Position value Share count Share price at filing
2024-06-30 $9.5M 367k 25.88

More positions owned by Braidwell

Guardant Health Note11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Novocure Note11/0 (Principal)
Nuvasive Note 0.375% 3/1 (Principal)
Neurocrine Biosciences (NBIX)
Cg Oncology (CGON)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Neogenomics Note 0.250% 1/1 (Principal)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Dexcom Note 0.375% 5/1 (Principal)
Guardant Health (GH)
Insulet Corp Note 0.375% 9/0 (Principal)
Legend Biotech Corp Sponsored Ads (LEGN)
Dexcom Note 0.250%11/1 (Principal)

View all positions for Braidwell

Top funds holding Dianthus Therapeutics

Bain Capital Life Sciences Investors
Avidity Partners Management
Fairmount Funds Management
RA Capital Management
VR Adviser
Octagon Capital Advisors
BlackRock
Vanguard Group
5AM Venture Management
Dr. Jeffrey R. Jay, M.D.
Henderson Group
Vestal Point Capital
Geode Capital Management
State Street Corporation
Braidwell

View all funds holding Dianthus Therapeutics